Delivery Order SPE2DB22D2005-SPE2DB25FJSE5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a $2,265.90 delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 MG/0.8 MLS, a pharmaceutical product used in the treatment of autoimmune conditions. This contract, awarded on August 19, 2025, represents a firm fixed price delivery order with an ultimate completion date of August 20, 2025. The award was made through open competition with no set-aside designation, and the product will be delivered to AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $1,888.25 delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded a $21,582.58 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 8, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat autoimmune conditions. This competitively awarded, firm fixed-price delivery order has a ceiling value of $2,265.90 and is set to complete by August 13, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this...
- The Defense Logistics Agency awarded a $5,303.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $9,166.50 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This contract type represents a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at...
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJSE5Delivery Order
The Defense Logistics Agency awarded a $5,506.33 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, which is set to be completed by August 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The delivery will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's comprehensive $999.99 billion IDC with DLA Troop Support Medical (contract number SPE2DX), which extends through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen has demonstrated capability to fulfill diverse medical supply requirements through competitive procurement processes. The award supports the Defense Health Agency and other federal healthcare systems with access to specialized pharmaceutical products needed for military personnel and beneficiary care.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 8/20/25 |